.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Cipla
Chinese Patent Office
Deloitte
Citi
McKesson
Colorcon
Chubb
Novartis
Medtronic

Generated: December 16, 2017

DrugPatentWatch Database Preview

Intercept Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for INTERCEPT PHARMS INC, and when can generic versions of INTERCEPT PHARMS INC drugs launch?

INTERCEPT PHARMS INC has one approved drug.

There are four US patents protecting INTERCEPT PHARMS INC drugs.

There are forty-two patent family members on INTERCEPT PHARMS INC drugs in twenty-three countries and four supplementary protection certificates in three countries.

Summary for Intercept Pharms Inc

International Patents:42
US Patents:4
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Intercept Pharms IncOCALIVAobeticholic acidTABLET;ORAL207999-002May 27, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
Intercept Pharms IncOCALIVAobeticholic acidTABLET;ORAL207999-002May 27, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Intercept Pharms IncOCALIVAobeticholic acidTABLET;ORAL207999-002May 27, 2016RXYesYes► Subscribe► SubscribeYY► Subscribe
Intercept Pharms IncOCALIVAobeticholic acidTABLET;ORAL207999-001May 27, 2016RXYesNo► Subscribe► Subscribe► Subscribe
Intercept Pharms IncOCALIVAobeticholic acidTABLET;ORAL207999-002May 27, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Intercept Pharms IncOCALIVAobeticholic acidTABLET;ORAL207999-001May 27, 2016RXYesNo► Subscribe► Subscribe► Subscribe
Intercept Pharms IncOCALIVAobeticholic acidTABLET;ORAL207999-001May 27, 2016RXYesNo► Subscribe► SubscribeY► Subscribe
Intercept Pharms IncOCALIVAobeticholic acidTABLET;ORAL207999-002May 27, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Intercept Pharms IncOCALIVAobeticholic acidTABLET;ORAL207999-001May 27, 2016RXYesNo► Subscribe► Subscribe► Subscribe
Intercept Pharms IncOCALIVAobeticholic acidTABLET;ORAL207999-001May 27, 2016RXYesNo► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Intercept Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,786,102Steroids as agonists for FXR► Subscribe
9,732,116Preparation and uses of obeticholic acid► Subscribe
9,732,117Steroids as agonists for FXR► Subscribe
8,969,330Steroids as agonists for FXR► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Intercept Pharms Inc Drugs

Country Document Number Estimated Expiration
European Patent Office1392714► Subscribe
Denmark1392714► Subscribe
Spain2248581► Subscribe
Germany60205891► Subscribe
Philippines12014502835► Subscribe
New Zealand719360► Subscribe
South Korea20150022974► Subscribe
Singapore10201607230S► Subscribe
Australia2002308295► Subscribe
Japan2017075169► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Intercept Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017 00025Denmark► SubscribePRODUCT NAME: OBETICHOLIC ACID; REG. NO/DATE: EU/1/16/1139 20161215
2017000034Germany► SubscribePRODUCT NAME: OBETICHOLSAEURE (OBETICHOLIC ACID); REGISTRATION NO/DATE: EU/1/16/1139 20161212
0877Netherlands► SubscribePRODUCT NAME: OBETICHOLZUUR; REGISTRATION NO/DATE: EU/1/16/1139 20161215
2017 00025Denmark► SubscribePRODUCT NAME: OBETICHOLIC ACID; REG. NO/DATE: EU/1/16/1139 20161215
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Federal Trade Commission
Moodys
Colorcon
Covington
Baxter
Merck
US Department of Justice
Argus Health
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot